$0.98
13.71% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US74275C2052
Symbol
PCSA

Processa Pharmaceuticals Inc Stock price

$0.98
-0.33 25.34% 1M
-0.82 45.67% 6M
-5.71 85.39% YTD
-8.26 89.42% 1Y
-113.22 99.14% 3Y
-209.02 99.53% 5Y
-1,978.62 99.95% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.12 13.71%
ISIN
US74275C2052
Symbol
PCSA
Sector

Key metrics

Market capitalization $3.20m
Enterprise Value $410.00k
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 0.86
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-11.79m
Free Cash Flow (TTM) Free Cash Flow $-11.12m
Cash position $2.89m
EPS (TTM) EPS $-5.02
Short interest 3.26%
Show more

Is Processa Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Processa Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Processa Pharmaceuticals Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Processa Pharmaceuticals Inc:

Buy
100%

Financial data from Processa Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.91 4.91
28% 28%
-
- Research and Development Expense 6.88 6.88
8% 8%
-
-12 -12
19% 19%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -12 -12
20% 20%
-
Net Profit -12 -12
47% 47%
-

In millions USD.

Don't miss a Thing! We will send you all news about Processa Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Processa Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
about 2 months ago
HANOVER, Md., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating NGC-Cap for the treatment of advanced or...
Neutral
GlobeNewsWire
3 months ago
HANOVER, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces that management will be participating in the following investor and industry conferences during the month of September:
Positive
InvestorPlace
4 months ago
Processa Pharmaceuticals (NASDAQ: PCSA ) stock is rising higher on Tuesday after the company posted an update from the Food and Drug Administration (FDA). The FDA has cleared Processa Pharmaceuticals for its Phase 2 clinical trial Next Generation Capecitabine (NGC-Cap).
More Processa Pharmaceuticals Inc News

Company Profile

Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its product pipeline is PCS499, which is use for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on October 2, 2017 and is headquartered in Hanover, MD.

Head office United States
CEO George Ng
Employees 13
Founded 2011
Website www.processapharmaceuticals.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today